Gainers

• ENvue Medical (NASDAQ:FEED) stock moved upwards by 33.5% to $1.91 during Tuesday's pre-market session. The company's market cap stands at $1.5 million.
• Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 22.37% to $8.15. The company's market cap stands at $122.1 million.
• Trinity Biotech (NASDAQ:TRIB) stock increased by 13.06% to $0.68. The company's market cap stands at $11.4 million.
• Tenaya Therapeutics (NASDAQ:TNYA) shares moved upwards by 11.45% to $0.84. The market value of their outstanding shares is at $163.0 million.
• FibroBiologics (NASDAQ:FBLG) shares rose 11.24% to $0.28. The market value of their outstanding shares is at $17.0 million.
• Valneva (NASDAQ:VALN) shares increased by 10.23% to $7.15. The company's market cap stands at $563.8 million. As per the news, the Q4 earnings report came out 4 days ago.

Losers

• Outlook Therapeutics (NASDAQ:OTLK) stock declined by 31.3% to $0.22 during Tuesday's pre-market session. The company's market cap stands at $23.5 million.
• Mira Pharmaceuticals (NASDAQ:MIRA) stock fell 9.34% to $1.02. The company's market cap stands at $47.1 million.
• Ensysce Biosciences (NASDAQ:ENSC) shares declined by 9.27% to $0.53. The market value of their outstanding shares is at $2.0 million.
• Zhengye Biotechnology (NASDAQ:ZYBT) shares decreased by 9.01% to $0.91. The company's market cap stands at $47.3 million.
• Quince Therapeutics (NASDAQ:QNCX) stock fell 8.37% to $0.09. The company's market cap stands at $5.6 million.
• Pulsenmore (NASDAQ:PLSM) shares declined by 8.19% to $3.7. The company's market cap stands at $26.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.